PI
BLUE

PEAK6 Investments’s bluebird bio BLUE Stock Holding History

PEAK6 Investments’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-700
Closed -$89K – 4456
2022
Q3 		$89K Buy
+700
New +$79.2K ﹤0.01% 4152
2021
Q3 		– Sell
-1,791
Closed -$742K – 5176
2021
Q2 		$742K Buy
+1,791
New +$710K ﹤0.01% 2864
2021
Q1 		– Sell
-8,299
Closed -$4.65M – 4862
2020
Q4 		$4.65M Buy
8,299
+1,420
+21% +$900K 0.01% 1110
2020
Q3 		$4.81M Buy
6,879
+5,497
+398% +$4.29M 0.01% 976
2020
Q2 		$1.09M Sell
1,382
-309
-18% -$233K ﹤0.01% 2001
2020
Q1 		$1.01M Sell
1,691
-2,022
-54% -$1.97M 0.01% 1531
2019
Q4 		$4.22M Buy
3,713
+347
+10% +$377K 0.02% 704
2019
Q3 		$4M Buy
3,366
+3,351
+22,340% +$5.12M 0.03% 817
2019
Q2 		$25K Buy
+15
New +$25.9K ﹤0.01% 3416
2018
Q4 		– Sell
-1,158
Closed -$2.19M – 4023
2018
Q3 		$2.19M Buy
+1,158
New +$2.39M 0.01% 1366

Other funds holding BLUE

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PEAK6 Investments's BLUE Position: Q3 2022 in Review

PEAK6 Investments sold out of bluebird bio (BLUE) in Q3 2022, closing a stake of 500 shares — an estimated $56.6K sold.

PEAK6 Investments first reported a position in BLUE in Q4 2018 and held it in 10 quarters. The position peaked at $2.48M in Q1 2020. 162 funds tracked by Wall St. Rank hold BLUE as of Q3 2022.

  • PEAK6 Investments reported no remaining bluebird bio position as of Q3 2022 after selling out during the quarter.
  • PEAK6 Investments sold 500 bluebird bio shares in Q3 2022, an estimated $56.6K.
  • PEAK6 Investments first reported a position in bluebird bio in Q4 2018 and held it in 10 quarters.
  • PEAK6 Investments's bluebird bio position peaked at $2.48M in Q1 2020.
  • 162 funds tracked by Wall St. Rank held bluebird bio as of Q3 2022.

Based on PEAK6 Investments's 13F filing for Q3 2022, filed 14 Nov 2022.